Download MendeleyDiscovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-beta-lactamases.
Hecker, S.J., Reddy, K.R., Lomovskaya, O., Griffith, D.C., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Sun, D., Sabet, M., Tarazi, Z., Parkinson, J., Totrov, M., Boyer, S.H., Glinka, T.W., Pemberton, O.A., Chen, Y., Dudley, M.N.(2020) J Med Chem 63: 7491-7507
- PubMed: 32150407
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01976
- Primary Citation Related Structures:
6V1J, 6V1M, 6V1O, 6V1P - PubMed Abstract:
Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory to inhibition by agents recently introduced. Most important among these are the class B (metallo) enzyme NDM-1 of Enterobacteriaceae and the class D (OXA) enzymes of Acinetobacter baumannii . Continuing the boronic acid program that led to vaborbactam, efforts were directed toward expanding the spectrum to allow treatment of a wider range of organisms. Through key structural modifications of a bicyclic lead, stepwise gains in spectrum of inhibition were achieved, ultimately resulting in QPX7728 ( 35 ). This compound displays a remarkably broad spectrum of inhibition, including class B and class D enzymes, and is little affected by porin modifications and efflux. Compound 35 is a promising agent for use in combination with a β-lactam antibiotic for the treatment of a wide range of multidrug resistant Gram-negative bacterial infections, by both intravenous and oral administration.
- Qpex Biopharma, Inc., 6275 Nancy Ridge Drive, Suite 100, San Diego, California 92121, United States.
Organizational Affiliation:
